Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain

Summary

To evaluate superiority of HDC in comparison to placebo in the treatment of chronic low-back pain in relation to pain, functional impairment, quality of life, and state of health during a 15-week treatment period.

Timeline

Start

2003-12

Primary completion

2007-05

Completion

2007-05

Outcome

Met primary endpoint

registry analysis (superiority or other test); Lymphdiaral Basistropfen (HDC) vs Placebo Solution; p = 0.0426; Wilcoxon (Mann-Whitney) NCT01049373 ↗

Drugs

Indications

No indication recorded.